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Safety of transgender hormone therapy
Transgender people still continue to face barriers to adequate
healthcare in the United States and theWorld despite increased ac-
ceptance and recognition of transgender and gender non-conforming
people over the past several decades by society and themedical com-
munity [1]. Several professional societies have released guidelines
for the hormonal management of transgender people including the
Endocrine Society and the World Professional Association for
Transgender Health [2,3]. However, many physicians still lack the
comfort level and training to provide adequate care for transgender
people [4,5]. Some physicians still question the safety of hormone
therapies for transgender people and are uncomfortable with pre-
scribing appropriate hormone therapy [6].
In a recent issue of Journal of Clinical & Translational Endocrinol-
ogy, Weinard and Safer [7] report a systematic literature review of
safety outcomes in transgender people receiving cross-hormone
therapy prescribed under medical supervision. They speciﬁcally
review the risks of thromboembolism, cancer, cardiovascular disease,
diabetes and insulin resistance, bone mineral density and mortal-
ity in both male to female (MTF) and female to male (FTM)
transgender people.
The authors noted that risks of thromboembolic disease in MTF
transgender people to be low based on several cohort studies with
an incidence of ~5% reported in past studies and approaching about
1% in more recent studies. The risks of thromboembolic disease also
seemed to be minimized with the use of transdermal estrogens in
a study reported by Ott et al. [8] who found 0 out of 162 MTF
transgender people to have developed a thromboembolic event. The
authors also reported an inconclusive risk of cancer amongMTF and
FTM transgender people based on mainly case reports and small
case series. They also commented that studies on bone density,
insulin resistance, and other laboratory parameters have been too
small to raise any safety concerns over cross-sex hormone therapy.
The authors also note in their review that there was no direct ev-
idence that hormone therapy itself increasedmortality in either MTF
and FTM transgender people.
These ﬁndings in this review byWeinand and Safer should help
physicians feel more comfortable in providing the hormone therapy
that transgender people seek from physicians and other health-
care providers. Transgender people may be at increased risk from
mortality as the risk of suicide is higher in this population compared
to the general population. Withholding hormone therapy or not pro-
viding the proper referrals for care may increase the suicide risk in
this population; although, there is inadequate evidence to know if
hormone therapy reduces the depression and suicide risk associ-
ated with being transgender. We need larger studies to conﬁrm that
hormone therapy under adequate medical supervision is safe and
which regimens are associated with the lowest morbidity and mor-
tality risks. Until these studies are conducted, physicians, especially
endocrinologists, should feel more comfortable prescribing cross sex
hormones as a safe therapy following established guidelines for
transgender people.
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